JP7290568B2 - 癌免疫療法のための併用療法での多重特異性抗体 - Google Patents

癌免疫療法のための併用療法での多重特異性抗体 Download PDF

Info

Publication number
JP7290568B2
JP7290568B2 JP2019533195A JP2019533195A JP7290568B2 JP 7290568 B2 JP7290568 B2 JP 7290568B2 JP 2019533195 A JP2019533195 A JP 2019533195A JP 2019533195 A JP2019533195 A JP 2019533195A JP 7290568 B2 JP7290568 B2 JP 7290568B2
Authority
JP
Japan
Prior art keywords
concept
seq
depends
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502198A (ja
JP2020502198A5 (enExample
Inventor
イアン キャンベル，ジェイミー
サンディ，ニコル
クリンクス，カサンドラ ヴァン
ジョン アーキンストール，スティーヴン
ゲルマシェウスキー，フォルカー
カービー，イアン
コズマック，ミハ
ギャラガー，トーマス
デアントニオ，セシリア
ギリース，スティーヴン，ダグラス
ジョン マコート，マシュー
チャールズ，アルフレッド サンソン，リチャード
ハニフ アリ，ムハンマド
リー，イー－チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1621782.0A external-priority patent/GB201621782D0/en
Priority claimed from GBGB1702339.1A external-priority patent/GB201702339D0/en
Priority claimed from GBGB1702338.3A external-priority patent/GB201702338D0/en
Priority claimed from GBGB1703071.9A external-priority patent/GB201703071D0/en
Priority claimed from US15/480,525 external-priority patent/US10604576B2/en
Priority claimed from TW106120564A external-priority patent/TWI640536B/zh
Priority claimed from GBGB1709818.7A external-priority patent/GB201709818D0/en
Priority claimed from PCT/GB2017/052352 external-priority patent/WO2018029474A2/en
Priority claimed from TW106126908A external-priority patent/TWI760352B/zh
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority claimed from PCT/GB2017/053826 external-priority patent/WO2018115859A1/en
Publication of JP2020502198A publication Critical patent/JP2020502198A/ja
Publication of JP2020502198A5 publication Critical patent/JP2020502198A5/ja
Priority to JP2023016174A priority Critical patent/JP7750887B2/ja
Application granted granted Critical
Publication of JP7290568B2 publication Critical patent/JP7290568B2/ja
Priority to JP2025157613A priority patent/JP2026001069A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019533195A 2016-12-20 2017-12-19 癌免疫療法のための併用療法での多重特異性抗体 Active JP7290568B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023016174A JP7750887B2 (ja) 2016-12-20 2023-02-06 癌免疫療法のための併用療法での多重特異性抗体
JP2025157613A JP2026001069A (ja) 2016-12-20 2025-09-24 癌免疫療法のための併用療法での多重特異性抗体

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
GBGB1621782.0A GB201621782D0 (en) 2016-12-20 2016-12-20 Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines
GB1621782.0 2016-12-20
GBGB1702338.3A GB201702338D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines
GB1702339.1 2017-02-13
GB1702338.3 2017-02-13
GB1703071.9 2017-02-24
GBGB1703071.9A GB201703071D0 (en) 2017-02-24 2017-02-24 Antibodies
US15/480,525 2017-04-06
US15/480,525 US10604576B2 (en) 2016-06-20 2017-04-06 Antibodies and immunocytokines
GB1709818.7 2017-06-20
TW106120564A TWI640536B (zh) 2016-06-20 2017-06-20 抗體
GBPCT/GB2017/051795 2017-06-20
TW106120562 2017-06-20
GBPCT/GB2017/051794 2017-06-20
PCT/GB2017/051796 WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies
GBGB1709818.7A GB201709818D0 (en) 2017-06-20 2017-06-20 Antibodies
PCT/GB2017/051794 WO2017220988A1 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
TW106120563A TW201803905A (zh) 2016-06-20 2017-06-20 用於免疫腫瘤學之多重專一性抗體
GBPCT/GB2017/051796 2017-06-20
TW106120563 2017-06-20
PCT/GB2017/051795 WO2017220989A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
TW106120564 2017-06-20
TW106120562A TWI784957B (zh) 2016-06-20 2017-06-20 免疫細胞介素
TW106126908A TWI760352B (zh) 2016-08-09 2017-08-09 抗ｉｃｏｓ抗體
TW106126908 2017-08-09
GBPCT/GB2017/052352 2017-08-09
PCT/GB2017/052352 WO2018029474A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
PCT/GB2017/053826 WO2018115859A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016174A Division JP7750887B2 (ja) 2016-12-20 2023-02-06 癌免疫療法のための併用療法での多重特異性抗体

Publications (3)

Publication Number Publication Date
JP2020502198A JP2020502198A (ja) 2020-01-23
JP2020502198A5 JP2020502198A5 (enExample) 2021-01-28
JP7290568B2 true JP7290568B2 (ja) 2023-06-13

Family

ID=61192960

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533195A Active JP7290568B2 (ja) 2016-12-20 2017-12-19 癌免疫療法のための併用療法での多重特異性抗体
JP2023016174A Active JP7750887B2 (ja) 2016-12-20 2023-02-06 癌免疫療法のための併用療法での多重特異性抗体
JP2025157613A Pending JP2026001069A (ja) 2016-12-20 2025-09-24 癌免疫療法のための併用療法での多重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023016174A Active JP7750887B2 (ja) 2016-12-20 2023-02-06 癌免疫療法のための併用療法での多重特異性抗体
JP2025157613A Pending JP2026001069A (ja) 2016-12-20 2025-09-24 癌免疫療法のための併用療法での多重特異性抗体

Country Status (3)

Country Link
US (2) US20200190191A1 (enExample)
EP (1) EP3559041A1 (enExample)
JP (3) JP7290568B2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019122882A1 (en) * 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP2023521228A (ja) * 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2022081841A1 (en) * 2020-10-16 2022-04-21 Fred Hutchinson Cancer Research Center Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
CA3219336A1 (en) * 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2023057534A1 (en) * 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
EP4525991A1 (en) * 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
MA53297A (fr) * 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
WO2019122882A1 (en) * 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Nature Immunology, 2013, Vol.14 No.2, p.152-161
Surgery Today, 2008, Vol.38 No.9, p.815-825
日本手の外科学会雑誌, 2005, Vol.22 NO.1, p.S86(1-Pb-7)
日本腎臓学会誌, 2004, Vol.46 No.3, p.249(P-113)
日本臨床免疫学会会誌, 2016.10.30, Vol.39 No.5, p.468-472
最新医学, 2003, Vol.58 No.12, p.2778-2785

Also Published As

Publication number Publication date
JP7750887B2 (ja) 2025-10-07
US20200190191A1 (en) 2020-06-18
JP2026001069A (ja) 2026-01-06
JP2020502198A (ja) 2020-01-23
EP3559041A1 (en) 2019-10-30
US20260049143A1 (en) 2026-02-19
JP2023055904A (ja) 2023-04-18

Similar Documents

Publication Publication Date Title
US20240343810A1 (en) Multispecific antibodies for immuno-oncology
US20260070979A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US20230348601A1 (en) Bispecific antibody for icos and pd-l1
US11965026B2 (en) Anti-PD-L1 and IL-2 cytokines
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
WO2018115859A1 (en) Multispecific antibody with combination therapy for immuno-oncology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230206

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230221

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230303

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230407

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230601

R150 Certificate of patent or registration of utility model

Ref document number: 7290568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250